Amphastar Pharmaceuticals, Inc
SWB:29A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Amphastar Pharmaceuticals, Inc
SWB:29A
|
US |
|
B
|
Barclays PLC
BMV:BCSN
|
UK |
|
Atenor SA
F:Z5S
|
BE |
|
C
|
Citizen Watch Co Ltd
XMUN:CTZ
|
JP |
|
Citizen Watch Co Ltd
F:CTZ
|
JP |
|
L
|
Lamar Advertising Co
F:6LA
|
US |
|
Tracsis PLC
F:4T2
|
UK |
|
S
|
Shanghai Electric Group Co Ltd
SWB:USR
|
CN |
|
N
|
Nissan Chemical Corp
F:NSC
|
JP |
|
W
|
Wooyang HC Co Ltd
KOSDAQ:101970
|
KR |
|
I
|
ideaForge Technology Ltd
NSE:IDEAFORGE
|
IN |
|
E
|
Eurazeo SE
XMUN:EUQ
|
FR |
|
Torrent Gold Inc
F:RV00
|
CA |
|
K
|
Karoon Energy Ltd
F:LBL
|
AU |
|
B
|
BWP Trust
OTC:BUNNF
|
AU |
|
Bright Real Estate Group Co Ltd
SSE:600708
|
CN |
|
F
|
Fomento de Construcciones y Contratas SA
XMUN:FCC
|
ES |
Intrinsic Value
Is 29A undervalued or overvalued?
See the intrinsic value estimate for 
Amphastar Pharmaceuticals, Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
29A looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with 29A’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Amphastar Pharmaceuticals Does
Amphastar Pharmaceuticals makes and sells injectable, inhalation, and intranasal medicines that are used in hospitals, emergency care, and other clinical settings. Its products include both branded and generic drugs, along with active pharmaceutical ingredients and certain drug-device combinations. The company focuses on medicines that are often hard to manufacture and supply consistently, which gives it a role in the lower-cost end of the pharmaceutical market.
- Headquarters
- United States of America US
- Employees
- 1 976
- IPO date
- Jun 25, 2014
Amphastar Pharmaceuticals has no economic moat
Amphastar Pharmaceuticals, Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysisLatest Earnings Call
- EPS
- $0.80
- Expected
- $0.51
- Surprise
- +56.9%
Revenue & Expenses Breakdown
Amphastar Pharmaceuticals, Inc
Earnings Waterfall
Amphastar Pharmaceuticals, Inc
The intrinsic value for Amphastar Pharmaceuticals, Inc (29A) under the Base Case is hidden EUR.
Compared with the current market price of 17.06 EUR, the stock appears hidden.